Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
Liquid biopsy (LB) is an emerging diagnostic tool that analyzes biomarkers in the blood (and possibly in other body fluids) to provide information about tumor genetics and response to therapy. This review article provides an overview of LB applications in human cancer with a focus on breast cancer p...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/7/1241 |
| _version_ | 1827747025976819712 |
|---|---|
| author | Carlotta Mazzitelli Donatella Santini Angelo Gianluca Corradini Claudio Zamagni Davide Trerè Lorenzo Montanaro Mario Taffurelli |
| author_facet | Carlotta Mazzitelli Donatella Santini Angelo Gianluca Corradini Claudio Zamagni Davide Trerè Lorenzo Montanaro Mario Taffurelli |
| author_sort | Carlotta Mazzitelli |
| collection | DOAJ |
| description | Liquid biopsy (LB) is an emerging diagnostic tool that analyzes biomarkers in the blood (and possibly in other body fluids) to provide information about tumor genetics and response to therapy. This review article provides an overview of LB applications in human cancer with a focus on breast cancer patients. LB methods include circulating tumor cells and cell-free tumor products, such as circulating tumor DNA. LB has shown potential in detecting cancer at an early stage, monitoring tumor progression and recurrence, and predicting patient response to therapy. Several studies have demonstrated its clinical utility in breast cancer patients. However, there are limitations to LB, including the lack of standardized assays and the need for further validation. Future potential applications of LB include identifying the minimal residual disease, early detection of recurrence, and monitoring treatment response in various cancer types. LB represents a promising non-invasive diagnostic tool with potential applications in breast cancer diagnosis, treatment, and management. Further research is necessary to fully understand its clinical utility and overcome its current limitations. |
| first_indexed | 2024-03-11T05:40:17Z |
| format | Article |
| id | doaj.art-e43580517fa64194aa0027da18b5cb4e |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T05:40:17Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-e43580517fa64194aa0027da18b5cb4e2023-11-17T16:29:49ZengMDPI AGDiagnostics2075-44182023-03-01137124110.3390/diagnostics13071241Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We GoingCarlotta Mazzitelli0Donatella Santini1Angelo Gianluca Corradini2Claudio Zamagni3Davide Trerè4Lorenzo Montanaro5Mario Taffurelli6Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, ItalyUnit of Pathology, IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40138 Bologna, ItalyUnit of Pathology, IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40138 Bologna, ItalyUnit of Oncology, IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40138 Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, ItalyDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, ItalyLiquid biopsy (LB) is an emerging diagnostic tool that analyzes biomarkers in the blood (and possibly in other body fluids) to provide information about tumor genetics and response to therapy. This review article provides an overview of LB applications in human cancer with a focus on breast cancer patients. LB methods include circulating tumor cells and cell-free tumor products, such as circulating tumor DNA. LB has shown potential in detecting cancer at an early stage, monitoring tumor progression and recurrence, and predicting patient response to therapy. Several studies have demonstrated its clinical utility in breast cancer patients. However, there are limitations to LB, including the lack of standardized assays and the need for further validation. Future potential applications of LB include identifying the minimal residual disease, early detection of recurrence, and monitoring treatment response in various cancer types. LB represents a promising non-invasive diagnostic tool with potential applications in breast cancer diagnosis, treatment, and management. Further research is necessary to fully understand its clinical utility and overcome its current limitations.https://www.mdpi.com/2075-4418/13/7/1241liquid biopsybreast cancerclinical managementcirculating tumor DNAcirculating tumor cells |
| spellingShingle | Carlotta Mazzitelli Donatella Santini Angelo Gianluca Corradini Claudio Zamagni Davide Trerè Lorenzo Montanaro Mario Taffurelli Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going Diagnostics liquid biopsy breast cancer clinical management circulating tumor DNA circulating tumor cells |
| title | Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going |
| title_full | Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going |
| title_fullStr | Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going |
| title_full_unstemmed | Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going |
| title_short | Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going |
| title_sort | liquid biopsy in the management of breast cancer patients where are we now and where are we going |
| topic | liquid biopsy breast cancer clinical management circulating tumor DNA circulating tumor cells |
| url | https://www.mdpi.com/2075-4418/13/7/1241 |
| work_keys_str_mv | AT carlottamazzitelli liquidbiopsyinthemanagementofbreastcancerpatientswherearewenowandwherearewegoing AT donatellasantini liquidbiopsyinthemanagementofbreastcancerpatientswherearewenowandwherearewegoing AT angelogianlucacorradini liquidbiopsyinthemanagementofbreastcancerpatientswherearewenowandwherearewegoing AT claudiozamagni liquidbiopsyinthemanagementofbreastcancerpatientswherearewenowandwherearewegoing AT davidetrere liquidbiopsyinthemanagementofbreastcancerpatientswherearewenowandwherearewegoing AT lorenzomontanaro liquidbiopsyinthemanagementofbreastcancerpatientswherearewenowandwherearewegoing AT mariotaffurelli liquidbiopsyinthemanagementofbreastcancerpatientswherearewenowandwherearewegoing |